When “Patient 2” was admitted to South Florida State Hospital for mental health treatment in 2023, doctors noted he suffered from two disorders, schizophrenia and psychosis. Five months later, after a ...
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy. The first patient has been dosed in a phase ...
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results